Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.
2.

Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials.

Vrecer M, Turk S, Drinovec J, Mrhar A.

Int J Clin Pharmacol Ther. 2003 Dec;41(12):567-77.

PMID:
14692706
3.
4.

Randomised trials of secondary prevention programmes in coronary heart disease: systematic review.

McAlister FA, Lawson FM, Teo KK, Armstrong PW.

BMJ. 2001 Oct 27;323(7319):957-62.

5.

Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis.

Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, Blechacz B, Bassler D, Wei X, Sharman A, Whitt I, Alves da Silva S, Khalid Z, Nordmann AJ, Zhou Q, Walter SD, Vale N, Bhatnagar N, O'Regan C, Mills EJ, Bucher HC, Montori VM, Guyatt GH.

BMJ. 2009 Feb 16;338:b92. doi: 10.1136/bmj.b92. Review.

6.

Lipid-lowering drug therapy in elderly patients.

Berthold HK, Gouni-Berthold I.

Curr Pharm Des. 2011;17(9):877-93. Review.

PMID:
21418034
7.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

8.

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.

Hayden M, Pignone M, Phillips C, Mulrow C.

Ann Intern Med. 2002 Jan 15;136(2):161-72.

PMID:
11790072
9.

Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis.

Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM.

Ann Intern Med. 2012 Aug 21;157(4):251-62. doi: 10.7326/0003-4819-157-4-201208210-00005. Review.

PMID:
22910936
11.

Cholesterol lowering and mortality: the importance of considering initial level of risk.

Smith GD, Song F, Sheldon TA.

BMJ. 1993 May 22;306(6889):1367-73. Erratum in: BMJ 1993 Jun 19;306(6893):1648.

12.

Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials.

Atkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB.

Ann Intern Med. 1993 Jul 15;119(2):136-45.

PMID:
8305001
13.
15.

Lipid-lowering for lower limb atherosclerosis.

Leng GC, Price JF, Jepson RG.

Cochrane Database Syst Rev. 2000;(2):CD000123. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD000123.

PMID:
10796489
16.

Hormone therapy and cardiovascular disease: a systematic review and meta-analysis.

Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM.

BJOG. 2006 Jan;113(1):5-14. Review.

17.

Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.

Gould AL, Davies GM, Alemao E, Yin DD, Cook JR.

Clin Ther. 2007 May;29(5):778-94. Review.

PMID:
17697899
18.

Lipid-lowering drug use and cardiovascular events after myocardial infarction.

Klungel OH, Heckbert SR, de Boer A, Leufkens HG, Sullivan SD, Fishman PA, Veenstra DL, Psaty BM.

Ann Pharmacother. 2002 May;36(5):751-7.

PMID:
11978147
19.

Drug treatment of hyperlipidemia in women.

Walsh JM, Pignone M.

JAMA. 2004 May 12;291(18):2243-52. Review.

PMID:
15138247
20.
Items per page

Supplemental Content

Support Center